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Abstract
In this study, we report that the transcription factor c-Maf is required for normal chondrocyte differentiation during endochondral bone
development. c-maf is expressed in hypertrophic chondrocytes during fetal development (E14.5–E18.5), with maximal expression in the
tibia occurring at E15.5 and E16.5, in terminally differentiated chondrocytes. In c-maf-null mice, fetal bone length is decreased 10%, and
hypertrophic chondrocyte differentiation is perturbed. There is an initial decrease in the number of mature hypertrophic chondrocytes at
E15.5 in c-maf-null tibiae, with decreased expression domains of collagen X and osteopontin, markers of hypertrophic and terminal
hypertrophic chondrocytes, respectively. By E16.5, there is an expanded domain of late hypertrophic, osteopontin-positive chondrocytes in
the c-maf/. This accumulation of hypertrophic chondrocytes persists and is still observed at 4 weeks of age. These data suggest that
c-Maf facilitates the initial chondrocyte terminal differentiation and influences the disappearance of hypertrophic chondrocytes. BrdU and
TUNEL analyses show normal proliferation rate and apoptosis in the c-maf-null. There is a specific decrease in MMP-13 expression at E15.5
in the c-maf-null. MMP-13 is known to be regulated by AP-1 and may also be a target of c-Maf. Thus, cartilage is a novel system in which
c-Maf acts during development, where c-Maf is required for normal chondrocyte differentiation.
© 2003 Elsevier Inc. All rights reserved.
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Introduction
c-Maf, the cellular homologue of the avian viral onco-
gene v-Maf, is a member of the basic leucine zipper (bZIP)
superfamily. Maf family transcription factors are divided
into two subgroups: the large Mafs, which includes c-Maf,
MafB, and neural retina-specific leucine zipper (Nrl); and
the small Mafs, including MafK, Maf F, MafG, and p18,
which lack the amino-terminal transactivating domain of
large Mafs. Maf proteins can act as homodimers or het-
erodimerize with other bZIP family members, including fos,
jun, and CREB/ATF family members (Kerppola and Cur-
ran, 1994). c-Maf binds a 13- to 14-bp consensus response
element (MARE), a sequence related to the AP-1 binding
site (Kataoka et al., 1994; Kerppola and Curran, 1994).
c-Maf is thought to be a developmental regulator in diverse
tissues, but to date, few cellular targets of c-Maf have been
identified.
In mouse, c-maf is reported to be strongly expressed in
the lens, kidney, and brain (Kawauchi et al., 1999). The rat
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Fig. 1. c-maf expression in embryonic and postnatal tibiae. Tibial sections from E14.5–E18.5 embryos and postnatal day 24 mice. (A) Bright field (BF) images
of sections stained with H&E, with hypertrophic chondrocytes (HC) and primary spongiosa (PS) bracketed. (B) In situ hybridization (dark field) showing
c-maf expression in hypertrophic chondrocytes, primary spongiosa, and perichondrium (P). (C) In situ hybridization showing collagen X expression in
hypertrophic chondrocytes. (D) In situ hybridization showing osteopontin expression in late hypertrophic chondrocytes and primary spongiosa. (E) Control
in situ hybridization using c-maf sense probe in E16.5 wild-type (/) tibia, c-maf anti-sense probe in E16.5 c-maf-null (/) tibia. Original magnification,
10.
Fig. 2. Phenotype and tibial morphology of wild-type and c-maf-null. (A) Thirty-day-old wild-type and c-maf-null littermates, showing small body size of c-maf-null.
(B–F) Tibiae from wild-type and c-maf-null littermates, stained with H&E (B–E) or safrinin O (F). (B) E14.5 tibiae, showing that wild-type and c-maf-null are
indistinguishable. (C) E15.5 tibiae, showing a reduction in the hypertrophic chondrocyte zone in the c-maf-null. (D) E16.5 tibiae, showing an expanded hypertrophic
zone, and delayed bone formation in the c-maf-null. (E) E18.5 tibiae, showing the hypertrophic chondrocyte zone is irregular in the c-maf-null. (F) Twenty-eight-day
postnatal tibiae, showing the expanded hypertrophic chondrocyte zone in the c-maf-null. RP, round proliferative chondrocytes; CP, columnar proliferative
chondrocytes; HC, hypertrophic chondrocytes; PS, primary spongiosa. Original magnification in (B–E), 4; in (F), 10.
52 H.E. MacLean et al. / Developmental Biology 262 (2003) 51–63
53H.E. MacLean et al. / Developmental Biology 262 (2003) 51–63
homologue of c-maf, maf-2, is expressed in a wide variety
of rat tissues, including spleen, kidney, intestine, muscle,
liver, lens, and cartilage (Sakai et al., 1997). However,
despite this widespread pattern of expression, little is known
about the function of c-Maf in most tissues. c-maf-null mice
have been generated, and have microphthalmia, caused by
failure of lens fiber elongation, due to loss of crystallin gene
regulation (Kawauchi et al., 1999; Kim et al., 1999c; Ring
et al., 2000). c-maf-null mice also show a severe impairment
of IL-4 production by T cells (Kim et al., 1999b). The IL-4
promoter contains an MARE and is directly upregulated by
c-Maf in the Th2 subgroup of T helper cells (Ho et al.,
1996). Other genes known to be upregulated by c-Maf
include the L7 gene in Purkinje cells (Kurschner and Mor-
gan, 1995) and the early myeloid cell gene CD13/AN
(Hegde et al., 1998). The detoxifying enzyme gene quinone
oxidoreductasel is repressed by c-Maf in liver cells (Dhak-
shinamoorthy and Jaiswal, 2002). c-Maf directly transacti-
vates the tumor suppressor gene p53 promoter in vitro, and
overexpression of c-maf induces p53-dependent cell death
in primary cell lines (Hale et al., 2000). However, the role
of c-Maf in the regulation of p53 expression in vivo remains
undetermined.
A long-form variant of c-Maf has recently been identi-
fied, which contains an extra 10 amino acids at the carboxyl
terminus of the protein (Huang et al., 2002). This variant,
termed Lc-Maf, is thought to arise from alternate splicing of
the c-maf gene, and it is expressed in areas of precartilagi-
nous mesenchymal condensation during embryonic bone
development. Lc-Maf interacts directly with the transcrip-
tion factor Sox9, and coexpression of Sox9 and Lc-Maf in
vitro causes synergistic activation of the Sox9 target gene
ColIIa1 (collagen II), which encodes a major matrix protein
in cartilage.
We have investigated the role of c-Maf in cartilage by
examining endochondral bone development in mice lacking
c-Maf. During endochondral bone formation, cartilaginous
structures develop and form the scaffold for subsequent
replacement by bone (reviewed in Mundlos and Olsen,
1997). Following initial mesenchymal condensation, chon-
drocytes in the developing bone proliferate to expand the
cartilage mold. Initially, the entire bone consists of prolif-
erating chondrocytes, then chondrocyte maturation begins
in the metaphysis of the bone, and less mature proliferating
chondrocytes are restricted to each end of the developing
bone. Maturation of chondrocytes involves formation of
columns of flattened proliferating cells, followed by exit of
cells from the cell cycle. Postmitotic cells further differen-
tiate into prehypertrophic and hypertrophic chondrocytes,
which secrete an extracellular matrix that becomes miner-
alized. Perichondrial cells surrounding the hypertrophic
chondrocytes differentiate into osteoblasts, forming the
bone collar; and blood vessels, osteoblasts, and osteoclasts
invade the mineralized hypertrophic chondrocytes. Oste-
oclasts/chondroclasts degrade the mineralized chondrocyte
matrix, and osteoblasts and hematopoietic cells replace the
mineralized cartilage with trabecular bone and bone mar-
row.
A number of key regulatory molecules that control early
chondrogenesis and proliferation have been identified, in-
cluding Sox9 at the initial condensation stage (Bi et al.,
1999); fibroblast growth factor (FGF), which acts through
the FGFR3 to negatively regulate chondrocyte proliferation
(Deng et al., 1996; Naski et al., 1996); and the PTHrP/
Indian hedgehog (Ihh) regulatory feedback loop, which up-
regulates chondrocyte proliferation and controls the timing
of cell cycle exit (Karp et al., 2000; Lanske et al., 1996;
Vortkamp et al., 1996). Factors controlling hypertrophic
chondrocyte differentiation and bone formation are also
beginning to be elucidated. The transcription factor cbfa1,
required for osteoblast differentiation, is also necessary for
normal chondrocyte differentiation. Cbfa1-null mice lack
all osteoblast formation, but also have abnormal hypertro-
phic chondrocyte differentiation. These mice exhibit failure
of terminal hypertrophic differentiation in the humerus and
femur and delayed chondrocyte differentiation elsewhere
(Inada et al., 1999; Kim et al., 1999a). Cbfa1 overexpression
induces hypertrophic differentiation both in vitro (Enomoto
et al., 2000) and in vivo (Takeda et al., 2001), and in vivo
expression of a dominant negative cbfa1 in chondrocytes
also suppresses hypertrophic differentiation and ossification
in all bones (Stricker et al., 2002; Ueta et al., 2001).
The expression of vascular endothelial growth factor
(VEGF) from hypertrophic chondrocytes regulates vascular
invasion of the cartilage. Blockade of VEGF signaling in
mice, via injection of a soluble chimeric form of the VEGF
receptor, blocks cartilage angiogenesis (Gerber et al., 1999).
This suppression of vascular invasion also causes expansion
of the hypertrophic chondrocyte zone and decrease in the
number of MMP-9-positive chondroclasts, indicating that
VEGF couples vascular invasion with resorption of miner-
alized chondrocyte matrix. It is likely that chondrocyte
apoptosis is coupled to vascular invasion (Gerber and Fer-
rara, 2000), although few regulators of apoptosis have been
identified. MMP-9 is required for normal hypertrophic
chondrocyte cell death. MMP-9 is expressed by osteoclasts/
chondroclasts, and in MMP-9-null mice, hypertrophic chon-
drocytes differentiate normally, but apoptosis, vasculariza-
tion, and ossification are delayed, resulting in progressive
lengthening of the hypertrophic chondrocyte region in the
bones (Vu et al., 1998). Other matrix metalloproteinases,
including MMP-13 (collagenase 3), are thought to play a
role in hypertrophic differentiation and vascular invasion
through matrix proteolysis, causing release of angiogenic or
growth factors. Terminal hypertrophic chondrocytes, which
express osteopontin, also express MMP-13; and inhibition
of MMP-13 suppresses terminal chondrocyte differentiation
in vitro (Wu et al., 2002).
In this report, we demonstrate that c-maf-null mice have
abnormal chondrocyte development, with terminal differen-
tiation of hypertrophic chondrocytes initially delayed, fol-
lowed by a subsequent expansion of the hypertrophic chon-
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drocyte domain in the growth plates of embryonic and
postnatal long bones. These findings indicate that c-Maf is
required for normal chondrocyte differentiation.
Materials and methods
Mice
c-maf-null mice were generated as described (Kim et al.,
1999c) and were backcrossed two to three generations onto
BALB/c. Wild-type and heterozygote controls were litter-
mates of c-maf homozygous nulls. Mice were genotyped by
Southern analysis as previously described (Kim et al.,
1999c). Animals were housed in sterilized microisolator
cages, fed autoclaved food and water, and handled in lam-
inar airflow hoods. All animal studies were undertaken
according to institutional guidelines.
Tissue preparation and histology
Adult bones were fixed in 10% neutral buffered formalin
for 24 h, then decalcified in 0.5 M EDTA, pH 7.4, for 10–14
days at 4°C before paraffin embedding. Embryonic bones
were fixed 24 h in 10% neutral buffered formalin, then
maintained in 70% ethanol without decalcification prior to
paraffin embedding. Serial 6-m sections were cut through
long bones. Sections were stained in hematoxylin and eosin
(H&E), or safrinin O, using standard protocols. Von Kossa
staining was performed on E15.5–E18.5 sections as de-
scribed (Page et al., 1996), and sections were counterstained
with methyl green (Vector).
In situ hybridization
In situ hybridization was performed by using a modifi-
cation of our previously described method (Lee et al., 1996).
Prehybridization and hybridization were performed exactly
as described, but following hybridization, slides were
washed by using the following modified protocol: slides
were briefly rinsed in 1 SSC, then washed in 2 SSC,
50% formamide at 52°C, 2 5 min. Slides were then rinsed
in 2 SSC, 2  1 min, then incubated 37°C, 30 min in 30
g/ml RNase A in 2 SSC. Slides were then rinsed again
in 2 SSC, 2 1 min, washed in 2 SSC, 50% formamide
at 52°C, 5 min, then dehydrated with increasing concentra-
tions of ethanol. Riboprobes were generated by using 35S-
UTP (Perkin Elmer Life Sciences) from cDNA templates of
the following genes: rat alkaline phosphatase (Noda et al.,
1987), mouse Bcl-2 (Nunez et al., 1990), mouse cbfa1
(Ducy et al., 1997), rat 1(II) collagen (collagen II) (Kohno
et al., 1984), mouse collagen X (Apte et al., 1992), mouse
Indian hedgehog (Ihh) (Bitgood and McMahon, 1995),
mouse MMP-9 (collagenase IV) (Reponen et al., 1994),
mouse MMP-13, mouse osteopontin (Nomura et al., 1988),
rat PTH receptor (Abou-Samra et al., 1992), and mouse
vascular endothelial growth factor (VEGF). The mouse
c-maf vector was constructed by using 410 bp of the
murine c-maf 3 untranslated region (UTR), from nucleotide
2250 to 2661. This probe does not detect the variant Lc-maf
transcript, which contains a different 3 UTR from c-maf
(Huang et al., 2002). Mouse p53 was obtained commer-
cially from Ambion (pTRI-p53-mouse antisense probe tem-
plate).
BrdU and TUNEL assays
For in utero labeling of embryos with 5-bromo-2-de-
oxyuridine (BrdU), timed pregnant females were injected
intraperitoneally with 10 mg/ml BrdU (Sigma), 1.2 mg/ml
5-fluoro-2-deoxyuridine (Sigma) in PBS, at 0.1 ml stock
per 10 g body weight. Embryos were harvested 1 h postin-
jection for E14.5 and E15.5 embryos, 2 h postinjection for
E16.5–E18.5 embryos. Following routine fixation, process-
ing, and sectioning, immunohistochemical detection of
BrdU was performed by using Zymed Laboratories’ BrdU
staining kit, according to the manufacturer’s instructions.
Tibial sections were counterstained with hematoxylin, and
the number of BrdU-positive and -negative chondrocytes in
the proliferating growth plate was quantitated on at least
three sections per embryo. Statistical analysis was per-
formed by using the Student’s t test to compare the mean of
c-maf / and / values.
TUNEL analysis was performed by using the ApoAlert
DNA fragmentation kit (Clontech). Paraffin tissue sections
were labeled according to the kit’s protocol, except that the
TdT terminal transferase was used at 50 U/slide, 2 rec-
ommended concentration. Sections were counterstained
with 0.01% Evan’s blue (Sigma) and mounted for fluores-
cent microscopic analysis in Vectorshield with DAPI (Vec-
tor). At each developmental stage, at least two wild-type
and two c-maf-null specimens were examined, using three
sections per tibia. The number of TUNEL-positive chon-
drocytes per tibia was counted, and chondrocytes were dis-
tinguished from surrounding perichondrium, primary spon-
giosa, and osteoclasts based on morphology.
Immunohistochemistry
Immunohistochemistry was performed by using the
TSA-biotin amplification system (Perkin Elmer Life Sciences).
Following routine preparation, paraffin sections were
cleared and rehydrated. Antigen retrieval was performed by
microwaving slides for 10 min at 95°C in citrate buffer
(8.2 mM sodium citrate, pH 6.0). Endogenous peroxidase
activity was quenched by incubation in 3% H2O2 in meth-
anol, 10 min, then slides were washed in dH2O 10 min.
Sections were blocked in blocking reagent (Perkin Elmer
Life Sciences) 30 min at room temperature, then incubated
1 h at room temperature with anti-p53 (FL-393) (Santa
Cruz), diluted 1:1000 in blocking reagent. Sections were
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washed in TNT buffer (50 mM Tris-Cl, 150 mM NaCl, pH
7.6, 0.05% Tween 20) 3  5 min, then incubated 30 min at
room temperature with biotin-conjugated anti-rabbit IgG
(Santa Cruz) at 1:500. TSA amplification was then per-
formed according to manufacturer’s instructions, with per-
oxidase detection utilizing DAB (Vector) as the chromagen.
Sections were counterstained with methyl green (Vector).
Results and discussion
c-maf is expressed in late hypertrophic chondrocytes
In rat, Sakai et al. (1997) previously showed that maf-1
and maf-2 are both expressed in E15.5 embryonic rat limb
and rib cartilage, and that immunoreactive Maf-1 and Maf-2
Fig. 3. Expression of p57, collagen X, and osteopontin in wild-type and c-maf-null tibiae. In situ hybridization performed on tibial sections from wild-type
and c-maf-null littermates. (A) E14.5 tibiae, showing normal expression domains of p57 (prehypertrophic and early hypertrophic chondrocytes) and collagen
X (hypertrophic chondrocytes) in the c-maf-null. (B) E15.5 tibiae, showing normal expression of p57, but reduced domain of collagen X and osteopontin
expression in hypertrophic chondrocytes in the c-maf-null. (C) E16.5 tibiae, showing expanded domain of collagen X and osteopontin expression in
hypertrophic chondrocytes in the c-maf-null. HC, hypertrophic chondrocytes; PS, primary spongiosa.
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protein is present in hypertrophic chondrocytes of the adult
rat femur. To localize chondrocyte expression of c-maf
more specifically, we performed in situ hybridization on
mouse embryonic tibiae from E14.5–E18.5 and postnatal
day 24 tibia (Fig. 1), using a probe in the 3 UTR that
recognizes c-maf but not the long variant Lc-maf. c-maf
expression was detected in hypertrophic chondrocytes at all
stages examined, with maximal expression at E15.5 and
E16.5 (Fig. 1B). Sense probe showed no signal, nor did
c-maf anti-sense probe used on c-maf/ sections (Fig.
1E). Collagen X is expressed by all hypertrophic chondro-
cytes, at high levels in early hypertrophic cells and lower
levels in late hypertrophic chondrocytes (Fig. 1C). In con-
trast, only the terminally differentiated hypertrophic chon-
drocytes express osteopontin, as do osteoblasts in the pri-
mary spongiosa (Fig. 1D). c-maf expression was not found
in all collagen X-expressing cells, but it was expressed by
all osteopontin-positive chondrocytes (Fig. 1B–D). The ex-
pression of c-maf also slightly preceded that of osteopontin,
with mRNA detectable at low levels in some hypertrophic
chondrocytes of the E14.5 tibia, when no osteopontin was
present, and in a slightly larger domain than that of os-
teopontin. These data indicate that c-maf is expressed pre-
dominantly in mature and terminally differentiated hyper-
trophic chondrocytes. c-maf was also expressed at low
levels in the perichondrium and in the primary spongiosa.
The long variant of c-maf, Lc-maf, is expressed in E10.5–
E12.5 mesenchymal condensations, but at later stages, ex-
pression is restricted to the perichondrium, with no expres-
sion in differentiated chondrocytes (Huang et al., 2002).
Thus, c-maf and Lc-maf are coexpressed in the perichon-
drium, but c-maf is uniquely found in hypertrophic chon-
drocytes.
Fig. 4. Proliferation and apoptosis in wild-type and c-maf-null tibiae. (A)
BrdU incorporation in E15.5 tibiae, showing equal percentage of BrdU-
positive chondrocytes (brown), and equal size of round proliferative (RP)
and columnar proliferative (CP) zones in wild-type and c-maf-null litter-
mates. Original magnification, 10. (B) TUNEL analysis in E15.5 tibiae,
showing fluorescein-labeled TUNEL-positive nuclei (green), counter-
stained with the nuclear stain DAPI (blue). TUNEL-positive cells are
predominantly seen in the bone collar (BC), with scattered positive chon-
drocytes (examples highlighted by yellow arrowhead); and no difference
between wild-type and c-maf-null. Original magnification, 20.
Fig. 5. p53 expression in wild-type and c-maf-null tibiae. In situ hybrid-
ization and immunohistochemistry performed on tibial sections from E15.5
wild-type and c-maf-null littermates. (A) In situ hybridization, showing
equivalent expression of p53 mRNA in hypertrophic chondrocytes of the
wild-type and the c-maf-null. Original magnification, 10. (B) Immuno-
histochemistry, showing predominant localization of p53 protein (brown)
in the bone collar (BC), with low levels present in mature hypertrophic
chondrocytes, and no difference between wild-type and c-maf-null. Sec-
tions counterstained with methyl green. Original magnification, 20.
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c-maf-null limbs are shortened, with expanded zones of
hypertrophic chondrocytes
c-maf/ mice were grossly normal in size at birth, but
by 4 weeks, homozygous null mice were generally one-third
the weight of their wild-type or heterozygote littermates
(Fig. 2A). This indicated a potential role for c-Maf in the
regulation of skeletal growth. However, because c-maf/
mice are blind, we could not rule out the possibility that
their small size was the result of a generalized failure to
thrive, caused by a reduced ability to feed. To exclude the
potential effects of nutritional status on growth, we chose to
focus on the role of c-Maf during embryonic bone devel-
opment, when expression of c-maf in chondrocytes is max-
imal. To examine the morphology of bones during devel-
opment, histological analysis was performed on the
forelimbs and hind limbs from embryos at E14.5–E18.5.
At E14.5, the central portion of the tibia is comprised of
hypertrophic chondrocytes, with proliferative chondrocytes
in each epiphyseal region. At this developmental stage,
bones from wild-type and c-maf-null littermates were indis-
tinguishable. There was no difference in the total length of
the tibia, and the degree of chondrocyte hypertrophy in the
central portion of the tibia was also similar, indicating
normal timing in the initial transition from proliferative to
hypertrophic chondrocytes (Fig. 2B).
The most dramatic morphological abnormalities were
observed at E15.5 and E16.5, corresponding to the time
points at which c-maf expression in chondrocytes is highest.
At E15.5, the total length of the long bones was reduced in
the c-maf/ embryos, with the c-maf-null tibial length
84.5  2.0% of wild-type or heterozygous. This reduction
in length was caused by a decrease in number of hypertro-
phic chondrocytes (Fig. 2C), with normal zones of round
and columnar proliferating chondrocytes. By E16.5, the
c-maf/ tibial length was 88.9  6.8% that of control
littermates. The proliferative chondrocyte zones were the
same size in the homozygous null and wild-type tibiae.
However, the c-maf-null tibia now contained an expanded
domain of hypertrophic chondrocytes, associated with de-
layed vascular invasion and markedly reduced ossification
in the center of the tibia (Fig. 2D). In some c-maf-null
embryos, the total bone length was the same as wild-type
littermates, but there was still an expansion of hypertrophic
chondrocytes and delayed bone formation, suggesting that
the expanded hypertrophic region is not caused simply by a
delay in the development of the entire bone.
At E17.5, the hypertrophic chondrocyte zone was still
expanded in the c-maf/ bones, but bone formation had
accelerated, so that mineralized bone comprised 35% of
the long-bone length in both the wild-type and c-maf-null
embryos. At E18.5, the appearance of the c-maf-null growth
plate was closer to normal, with irregularity in the thickness
of the hypertrophic zone, but a relative normalization of the
expanded hypertrophic chondrocyte domain (Fig. 2E).
However, total long-bone length was still reduced, with
average c-maf-null tibial length 90.7  3.3% of wild-type.
In 4-week postnatal c-maf/ mice, the tibial growth plate
also contained normal layers of resting and proliferative
chondrocytes, but the hypertrophic chondrocyte domain
was expanded in length approximately threefold compared
with control littermates (Fig. 2F), consistent with the phe-
notype observed in the embryonic mice. These morpholog-
ical findings suggested a possible defect in terminal differ-
entiation or apoptosis of hypertrophic chondrocytes in
c-maf-null mice. Therefore, we went on to characterize
more fully stages at which c-maf-null chondrocytes showed
abnormal development.
Expression domain of markers of hypertrophic
chondrocytes is abnormal
To precisely define which cells were affected by absence
of c-Maf, in situ hybridization was performed on E14.5–
E18.5 bones, probing with markers of different chondrocyte
populations. At all stages, c-maf/ bones showed normal
expression of genes expressed by proliferative and prehy-
pertrophic chondrocytes, including collagen II (prolifera-
tive); and Ihh, PTH receptor, p57, and alkaline phosphatase
(prehypertrophic and early hypertrophic) (Fig. 3, and data
not shown).
Collagen II is a target of the transcription factor Sox9,
and a recent report showed that Sox9 and Lc-Maf can
synergistically activate the expression of collagen II in vitro
(Huang et al., 2002). In the same study, c-Maf was also
reported to show a lesser, but still synergistic, activation of
the ColIIa1 enhancer element in conjunction with Sox9.
Lc-Maf is thought to arise from alternate splicing of the
c-maf gene; therefore, c-maf/ mice would lack both
c-Maf and Lc-Maf. The c-maf-null animals showed normal
levels of collagen II expression both in proliferative chon-
drocytes and also in prehypertrophic chondrocytes (data not
shown), where levels of active, phosphorylated Sox9 are
maximal (Huang et al., 2001). This indicates that neither
c-Maf nor Lc-Maf is required for normal collagen II ex-
pression in developing chondrocytes, and suggests that ei-
ther Sox9 alone or other transcription factors are the major
regulators of collagen II expression in vivo.
We also examined the expression of collagen X and
osteopontin, genes that are expressed by hypertrophic chon-
drocytes. At E14.5, the expression domain of collagen X
was normal in the c-maf-null tibia (Fig. 3A). At E15.5,
when the first histological abnormality is detectable in the
c-maf/ tibia, the intensity of collagen X expression was
also normal (Fig. 3B). However, the expression domain of
collagen X was decreased in the homozygous-null, consis-
tent with the reduction in the number of late hypertrophic
chondrocytes. Similarly, the expression of the terminal hy-
pertrophic chondrocyte marker osteopontin was also equal
in intensity, but reduced in area, in the c-maf-null (Fig. 3B),
indicating a reduction in the number of terminally differen-
tiated hypertrophic chondrocytes at this stage. These data
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suggest that c-Maf facilitates the initial progression of ter-
minal differentiation in chondrocytes.
At E16.5, the expression domain of collagen X was
expanded in the c-maf/ tibia (Fig. 3C), consistent with
the morphological observation of the persistence of hyper-
trophic chondrocytes at this stage. More particularly, the
region of terminal hypertrophic chondrocytes, which ex-
press high levels of osteopontin and lower levels of collagen
X, was also expanded in the c-maf-null tibia (Fig. 3C). This
indicates that the expanded hypertrophic domain is caused
by an increase in the number of late hypertrophic chondro-
cytes, the cells that normally express c-maf (Fig. 1B). Thus,
although the absence of c-Maf initially causes a delay in
terminal differentiation, this is then followed by an accu-
mulation of terminally differentiated hypertrophic chondro-
cytes.
Chondrocyte proliferation and apoptosis are normal in
c-maf null
The expansion of the hypertrophic chondrocyte zone
observed at E16.5 and later stages could potentially occur
by increased cell proliferation giving rise to a larger pool of
hypertrophic cells. It has previously been shown that, in
posterior lens cells of c-Maf-deficient animals, the region of
BrdU-positive, proliferating cells is expanded, indicating
that c-Maf is required for maintaining normal cell cycle exit
in the lens (Ring et al., 2000; Yoshida et al., 2001). There-
fore, we measured chondrocyte proliferation by in utero
labeling of embryos with BrdU. The percentage of BrdU-
positive, proliferating chondrocytes was the same in tibiae
from wild-type and c-maf-null embryos at both early
(E14.5, E15.5) and late (E17.5, E18.5) stages of develop-
ment (Table 1). There was also no difference in the size of
the BrdU-positive chondrocyte regions in the wild-type and
c-maf/ tibiae (Fig. 4A). These results are consistent with
our finding that c-maf is expressed in terminally differenti-
ated, postproliferative chondrocytes and suggest that c-Maf
does not regulate chondrocyte proliferation.
c-Maf has been shown to induce apoptosis in myeloid
progenitor cells (Hegde et al., 1999), through inhibition of
Myb-dependent Bcl-2 expression and other Myb-indepen-
dent pathways. A decrease in apoptosis of c-maf-null chon-
drocytes could potentially lead to the observed persistence
of terminal hypertrophic chondrocytes. Therefore, to quan-
titate apoptosis, TUNEL labeling of E14.5–E18.5 tissue
sections was performed to identify end-stage apoptotic
chondrocytes. In all sections, the number of TUNEL-posi-
tive cells in cartilage was significantly lower than in sur-
rounding tissues, including muscle, bone collar, and skin.
There were few TUNEL-positive chondrocytes in the tibia
at any developmental stage examined, except E15.5, the
time when vascular invasion commences and when there is
the greatest expanse of late hypertrophic chondrocytes. The
number of TUNEL-positive chondrocytes varied between
zero and eight per growth plate, in both wild-type and
c-maf-null sections (Fig. 4B). There was no difference in the
mean number of apoptotic chondrocytes in wild-type versus
c-maf/ tibiae. However, because of the low and variable
number of TUNEL-labeled chondrocytes in all sections,
subtle differences in apoptosis rate may have been missed.
Expression of Bcl-2 was low in chondrocytes, and we did
not observe any difference between levels of Bcl-2 mRNA
in wild-type and c-maf/ tibiae (data not shown). Using
immunohistochemistry, we examined the expression of a
number of other markers of apoptosis, including cleaved
caspase 3, cleaved cytokeratin 18, and cleaved poly(ADP-
ribose) polymerase (PARP) (data not shown). However, we
were unable to identify any other reliable, quantitative
marker of apoptosis in chondrocytes. Thus, we were unable
to quantitate any difference in apoptosis rate between wild-
type and c-maf-null chondrocytes, although we do not rule
out the possibility that a more sensitive measure of apopto-
sis would identify differences.
Expression of p53, a known c-Maf target gene, is normal
in chondrocytes
In vitro, p53 can be upregulated by c-Maf to induce
apoptosis (Hale et al., 2000). Studies in rheumatoid arthritis
show that p53 is expressed in arthritic lesions (Sun and
Cheung, 2002) and may play a role in articular chondrocyte
apoptosis (Yatsugi et al., 2000); however, little is known
about the potential role of p53 in chondrocyte apoptosis
during normal growth plate development. p53-null embry-
onic mice have been reported to have shortened long bones
and abnormal chondrocyte apoptosis (Ohyama et al., 1997).
In addition, p53 protein has been identified in chondrocytes,
associated with increased apoptosis, during degeneration of
Meckel’s cartilage (Trichilis and Wroblewski, 1997), sug-
gesting the possibility of a role for p53 in normal chondro-
Table 1
Chondrocyte proliferation rate in wild-type and c-maf-null tibiae
Stage % BrdU-positive cellsa
Wild-type c-maf/
E14.5 32.4 4.0 33.9 0.6
E15.5 27.5 2.4 25.8 4.9
E17.5 16.2 0.6 17.2 2.7
E18.5 18.7 2.4 20.6 4.2
a Mean  S.D.
Note. Embryos were labeled with BrdU in utero, for 1 h (E14.5, E15.5)
or 2 h (E17.5, E18.5), and immunohistochemical detection of BrdU was
performed on tibial sections. Proliferation rate was determined by counting
chondrocytes in a defined region of the growth plate, which contained only
proliferating cells and excluded the regions of prehypertrophic and hyper-
trophic chondrocytes, and the peripheral, perichondrial-like cells. Within
this region, all BrdU-positive (brown) and -negative (blue) nuclei were
counted, and the percentage of BrdU-positive chondrocytes was calculated
by the number of positive chondrocytes divided by the total number of
chondrocytes. No statistical difference in proliferation rate between wild-
type and c-maf-null was observed at any stage examined.
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cyte development. Therefore, we examined p53 expression
in c-maf-null tibiae. In situ hybridization for p53 at E15.5
and E16.5 showed normal expression, with low-level signal
detectable in the hypertrophic chondrocytes of all genotypes
(Fig. 5A). Similarly, p53 immunohistochemistry also
showed no difference in p53 protein levels between wild-
type and c-maf/ embryos. p53 protein was detected most
strongly in osteoblasts of the bone collar in all genotypes
(Fig. 5B), where maximal TUNEL-labeling occurred, with
low levels observed in late hypertrophic chondrocytes.
Thus, although previous in vitro studies have shown that
p53 is a target of c-Maf, c-Maf is not a major regulator of
p53 expression in chondrocytes.
Normal expression of regulators of hypertrophic
differentiation, osteoblastic differentiation,
and vascular invasion
We examined the expression of other regulators of hy-
pertrophic chondrocyte differentiation and vascular inva-
sion to identify possible downstream targets of c-Maf.
Cbfa1 is expressed in both early and late hypertrophic
chondrocytes. At E14.5–E18.5, levels of cbfa1 were com-
parable between wild-type and c-maf/, and consistent
with the number of hypertrophic chondrocytes present (Fig.
6A). Thus, early hypertrophic chondrocyte differentiation,
as measured by cbfa1 expression, is normal in the absence
of c-Maf. This indicates that c-Maf acts downstream of
cbfa1 in the chondrocyte differentiation process.
We have shown that c-maf is also expressed in osteo-
blasts (Fig. 1B). Cbfa1 is also expressed by osteoblasts, and
normal cbfa1 expression was observed in the perichondrium
and bone collar of the c-maf-null at E15.5 (Fig. 6A) and
later stages (data not shown). Similarly, osteopontin is ex-
pressed in mature osteoblasts, and expression was normal in
the c-maf/ (Fig. 3B and C), as was alkaline phospha-
tase, another osteoblastic marker (data not shown). Al-
though c-maf is expressed in the perichondrium and primary
spongiosa, we did not observe any defect in osteoblastic
differentiation in the c-maf-null.
The accumulation of hypertrophic chondrocytes may
have occurred because of a defect in vascular invasion or
Fig. 6. Regulators of hypertrophic differentiation and vascular invasion in wild-type and c-maf-null tibiae. Tibial sections from E15.5 wild-type and c-maf-null
littermates. In situ hybridization, showing morphological stage-appropriate expression of (A) Cbfa1, (B) VEGF, (C) MMP-9. (D) Von Kossa staining,
showing normal matrix mineralization (black) in chondrocytes and bone collar, sections counterstained with methyl green. Original magnification, 10.
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osteoclast/chondroclast function. Therefore, we examined
the expression of VEGF and MMP-9, genes known to be
required for normal vascular invasion, at E15.5–E18.5.
There was strong expression of VEGF in the c-maf/
hypertrophic chondrocytes (Fig. 6B), ruling out loss of
VEGF as the cause of delayed vascular invasion. Similarly,
MMP-9 expression was consistent with the stage of vascular
invasion, with strong expression in chondroclasts at the
chondro-osseus border in both wild-type and c-maf-null
tibiae (Fig. 6C), suggesting normal osteoclast/chondroclast
function.
Vascular invasion also requires normal matrix mineral-
ization; therefore, we stained sections with von Kossa to
identify mineralized bone and cartilage matrix (Fig. 6D).
The matrix of both the hypertrophic chondrocytes and the
bone collar of the c-maf/ tibia showed normal mineral-
ization at all stages examined (E15.5–E18.5). Thus, al-
though the absence of c-Maf causes an initial developmental
delay and subsequent accumulation of hypertrophic chon-
drocytes, these chondrocytes lacking c-Maf are capable of
producing and mineralizing matrix normally.
Decreased expression of MMP-13 at E15.5
Because we previously determined that c-maf is ex-
pressed in late hypertrophic chondrocytes (Fig. 1), which
also express MMP-13, we examined the expression of
MMP-13 in c-maf-null mice. At E16.5–E18.5, the expres-
sion domain of MMP-13 was expanded in the c-maf/
(Fig. 7A and B), as was observed for collagen X and
osteopontin, confirming the expansion of the mature hyper-
trophic chondrocytes at these stages. However, at E15.5,
both the expression domain and the intensity of MMP-13
expression were markedly reduced in the c-maf/ com-
pared with wild-type (Fig. 7C). This difference in expres-
sion was observed in at least two embryos of each genotype,
in at least two independent in situ hybridization experi-
ments, and raises the possibility that MMP-13 is a direct
target of c-Maf.
AP-1 and cbfa1 are known to regulate MMP-13 expres-
sion (D’Alonzo et al., 2002; Hess et al., 2001; Selvamuru-
gan et al., 1998), and functional AP-1 sites identified in the
mouse MMP-13 promoter have 13 out of 14 bp conserved
with a c-Maf MARE in the crystallin gene promoter (Ring
et al., 2000). At E15.5, cbfa1 expression is normal, yet
MMP-13 is reduced; thus, it is plausible that c-Maf is
required for upregulation of MMP-13. Furthermore, mice
lacking MMP-13 also show accumulation of hypertrophic
chondrocytes during endochondral bone development
(Krane, 2003), as we observed in the c-maf-null mice. How-
ever, this decreased MMP-13 expression in the c-maf-null
embryos was transient, observed only at E15.5. Therefore, if
MMP-13 is regulated by c-Maf, then the subsequent in-
crease in MMP-13 expression observed in the c-maf-null
may potentially occur through the actions of other Maf
family members, or AP-1.
Because the decrease in MMP-13 expression is only
transient, we do not believe that this loss of expression
causes the continued expansion of the hypertrophic domain
Fig. 7. MMP-13 expression in wild-type and c-maf-null tibiae. In situ
hybridization performed on tibial sections from wild-type and c-maf-null
littermates. (A) E16.5 tibiae, and (B) E18.5 tibiae, showing expanded
domain but normal intensity of MMP-13 expression in late hypertrophic
chondrocytes in the c-maf-null. (C) E15.5 tibiae, showing reduced domain
and reduced intensity of MMP-13 expression in late hypertrophic chon-
drocytes in the c-maf-null. HC, hypertrophic chondrocytes; PS, primary
spongiosa. Original magnification, 10.
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in the c-maf-null. The accumulation of hypertrophic chon-
drocytes persists long after MMP-13 expression becomes
normal, suggesting that aberrant expression of other, un-
known c-Maf target genes contributes to this abnormality.
We also cannot rule out the possibility that the decrease in
MMP-13 expression in the c-maf-null is simply a conse-
quence of the delay in chondrocyte differentiation. We have
shown that at E15.5 there is a reduction in the number of
terminal hypertrophic chondrocytes, as determined by the
expression of the late hypertrophic marker osteopontin.
Nevertheless, although the expression domain of osteopon-
tin is smaller in the c-maf/ tibia, the intensity of expres-
sion is not reduced in the absence of c-Maf. This suggests
that at E15.5 there is a reduction in the total number of late
hypertrophic chondrocytes, but that those present are fully
mature and capable of expressing normal levels of os-
teopontin and also inducing normal matrix mineralization.
In contrast, the decreased intensity of MMP-13 expression
means either that MMP-13 is expressed by an even later
subset of chondrocytes, which are further delayed in the
c-maf-null; or that there is a specific decrease in MMP-13
expression in the absence of c-Maf. Thus, although our data
are consistent with the possibility that c-Maf directly regu-
lates MMP-13 expression, further in vitro experiments
would be required to confirm this hypothesis.
In conclusion, we have shown that c-maf-null mice have
abnormal chondrocyte development, with terminal differen-
tiation of hypertrophic chondrocytes initially delayed, fol-
lowed by a subsequent expansion of the hypertrophic chon-
drocyte domain in the growth plates of embryonic and
postnatal long bones. We were unable to quantitate a dif-
ference in apoptosis rate between wild-type and c-maf-null
chondrocytes. Expression of regulators of chondrocyte hy-
pertrophy and vascular invasion, including cbfa1, MMP-9,
and VEGF, was normal. However, we identified a specific
decrease in MMP-13 expression at E15.5 in the absence of
c-Maf, suggesting the possibility that MMP-13 is regulated
by c-Maf. These findings indicate that c-Maf plays a role in
at least two stages of hypertrophic chondrocyte develop-
ment: the regulation of the timing of initial terminal differ-
entiation, prior to vascular invasion; and the regulation of
the disappearance of hypertrophic chondrocytes, which may
be related to chondrocyte apoptosis or vascular invasion.
Thus, our studies have identified cartilage as a novel devel-
opmental system in which c-Maf acts, where c-Maf is re-
quired for normal chondrocyte differentiation during endo-
chondral bone formation.
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